The impact of gap duration on local control in anal canal carcinoma treated by split-course radiotherapy and concomitant chemotherapy.
about
Radiotherapy versus combined modality therapy for anal carcinomaImpact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11.Higher radiation dose with a shorter treatment duration improves outcome for locally advanced carcinoma of anal canalConcurrent cisplatin, continuous infusion fluorouracil and radiotherapy followed by tailored consolidation treatment in non metastatic anal squamous cell carcinomaChemo-radiation with or without mandatory split in anal carcinoma: experiences of two institutions and review of the literature.Radiation therapy of anal canal cancer: from conformal therapy to volumetric modulated arc therapyComparison of four 3D conformal treatment techniques to optimise radiotherapy treatment for anal cancerChemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option.Dose planning objectives in anal canal cancer IMRT: the TROG ANROTAT experienceIMRT for locally advanced anal cancer: clinical experience of the Montpellier Cancer CenterChemotherapeutic options in the management of anal cancer.Comparison of anal cancer outcomes in public and private hospital patients treated at a single radiation oncology center.Comparison of elective inguinal node irradiation techniques in anal cancer.Optimal organ-sparing intensity-modulated radiation therapy (IMRT) regimen for the treatment of locally advanced anal canal carcinoma: a comparison of conventional and IMRT plansSurgical salvage therapy of anal cancer.Quality Research in Radiation Oncology analysis of clinical performance measures in the management of gastric cancer.Chemoradiotherapy in squamous cell carcinoma of the anal canal: a single institution experience.Evaluation of planned treatment breaks during radiation therapy for anal cancer: update of RTOG 92-08.Sphincter preservation in anal cancer: a brief review.Prognostic factors for squamous cell cancer of the anal canal.Concurrent chemoradiotherapy for squamous cell carcinoma of the anus using a shrinking field radiotherapy technique without a boost.Initial Results from the Royal College of Radiologists' UK National Audit of Anal Cancer Radiotherapy 2015.HDR brachytherapy for anal cancer.Shifting paradigm in the management of anal canal carcinoma.Advances in the Management of Anal Cancer.Intensity-modulated radiotherapy for squamous cell carcinoma of the anal canal: efficacy of a low daily dose to clinically negative regions.Image-guided IMRT with simultaneous integrated boost as per RTOG 0529 for the treatment of anal cancer.German-Austrian guidelines on anal dysplasia and anal cancer in HIV-positive individuals: prevention, diagnosis, and treatment.Clinical outcome in patients treated with simultaneous integrated boost - intensity modulated radiation therapy (SIB-IMRT) with and without concurrent chemotherapy for squamous cell carcinoma of the anal canal.Treatment interruption and discontinuation in radiotherapy for rectal cancer.Role of brachytherapy in the treatment of cancers of the anal canal. Long-term follow-up and multivariate analysis of a large monocentric retrospective series.Dosimetric parameters predictive of acute gastrointestinal toxicity in patients with anal carcinoma treated with concurrent chemotherapy and intensity-modulated radiation therapy.Compliance to the prescribed overall treatment time (OTT) of curative radiotherapy in normal clinical practice and impact on treatment duration of counteracting short interruptions by treating patients on Saturdays.Treatment interruption during radiation therapy: Experience at a single institution in the Republic of Korea.Brachytherapy boost after chemoradiation in anal cancer: a systematic reviewRecent advances in the management of anal cancerComparing simultaneous integrated boost vs sequential boost in anal cancer patients: results of a retrospective observational study
P2860
Q24247566-9E13D0B2-AFCF-469D-AE95-C4FA593FD87BQ33721749-E3C63E14-D499-4878-AA07-563840C0F5F6Q33787728-83B91F86-85FE-43F8-92B7-D7B8D808C707Q33811309-70E4FB15-F01D-4277-A28B-7DADF56C320AQ33888085-14727CA7-CB5C-413E-BAEE-C0C7584E59C7Q34584811-2A2E11DB-1080-48AE-927F-B7966DC9F2F4Q34803620-41E34E5F-8132-48B5-B593-2E9747A7CCB3Q35678065-BA9FC714-036E-47CD-8E53-014B5B2BAE60Q35718077-54980147-79A2-4914-93AF-96A7FC12B379Q35927962-5CED59E5-B5AF-41CC-B0A1-E034422D656EQ35967329-19561840-4200-479E-A3F0-CD04EAEF3A21Q36062623-56518DC4-780E-41A4-A5CE-889797E7A96CQ36196016-D083F65B-4C0B-4D83-BC74-47A6E2C923B2Q36389393-C5732C29-D26E-45A5-8869-5006C6299FA3Q36496261-FE3C245F-209E-4563-B04C-3160A220F0B5Q36532854-15E7F0DE-EEAD-4093-852C-AA23CEEBCE71Q36786775-C9E67814-DF2F-441F-9560-479CE9B13306Q36944546-BA06DB97-3135-4710-BED2-D636FB490A1FQ37005884-BCDED18E-FFFC-4CE9-8ED4-49D9A65A47DBQ37072485-079B1698-7E75-4200-B074-67CAF8E0C907Q37340391-896D5E2F-ECB3-4FB6-A45F-F2A1C9F08137Q37638312-5D2F436E-E0D6-42DE-8E9F-1EF226976535Q38225134-59E62B7D-3621-4E52-A4DB-8E9407053E78Q38272464-5B3C7ABC-C49D-4A4E-850B-EE7C68BD5DB3Q38746232-FA35108E-A9DC-4C38-9BD1-A2565E3F352EQ38783988-491189D6-0C18-445E-B2EE-414C5D2F3D5EQ40063703-E777F5FA-7CBB-49F6-9DFE-84777706DA70Q40892448-3F764327-098D-44AC-B0BE-AAC37C55A835Q40909528-EA53E4C0-962B-4F67-A20C-5E384536855DQ43194629-C23A2B4F-3DEA-4FDC-813D-1FBCBE3C1259Q43409549-5694FE96-02B1-41AC-9930-9131811F5C50Q43905213-7EDE7884-3072-470A-9F6D-7875A4788897Q46818658-F079167A-C666-467C-9358-3ADFD0C7F705Q48589202-0BA6E6F9-A162-4AF7-9052-DA56E0E66422Q56380424-C4C4CE70-8C70-4359-9209-E4F7AD949988Q57821008-B7C10496-82C9-491C-96BA-A1A9F31E7808Q58755495-20980E26-4657-44BA-B33F-4D87EF80C799
P2860
The impact of gap duration on local control in anal canal carcinoma treated by split-course radiotherapy and concomitant chemotherapy.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
The impact of gap duration on ...... and concomitant chemotherapy.
@en
The impact of gap duration on ...... and concomitant chemotherapy.
@nl
type
label
The impact of gap duration on ...... and concomitant chemotherapy.
@en
The impact of gap duration on ...... and concomitant chemotherapy.
@nl
prefLabel
The impact of gap duration on ...... and concomitant chemotherapy.
@en
The impact of gap duration on ...... and concomitant chemotherapy.
@nl
P2093
P1476
The impact of gap duration on ...... and concomitant chemotherapy.
@en
P2093
P304
P356
10.1016/S0360-3016(01)01510-3
P407
P577
2001-07-01T00:00:00Z